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Abstract
Background: Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-
methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear
because of conflicting results. We hypothesized that some of the confusion in the literature might arise
from differences in efficacy of different statins. We used a large database to compare the action of several
different statins to investigate whether some statins might be differentially associated with a reduction in
the incidence of dementia and Parkinson's disease.
Methods: We analyzed data from the decision support system of the US Veterans Affairs database, which
contains diagnostic, medication and demographic information on 4.5 million subjects. The association of
lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models
for subjects taking statins compared with subjects taking cardiovascular medications other than statins,
after adjusting for covariates associated with dementia or Parkinson's disease.
Results: We observed that simvastatin is associated with a significant reduction in the incidence of
dementia in subjects ≥65 years, using any of three models. The first model incorporated adjustment for
age, the second model included adjusted for three known risk factors for dementia, hypertension,
cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index,
which is an index that provides a broad assessment of chronic disease. Data were obtained for over
700000 subjects taking simvastatin and over 50000 subjects taking atorvastatin who were aged >64 years.
Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44–
0.48, p < 0.0001) and 0.91 (CI 0.80–1.02, p = 0.11), respectively. Lovastatin was not associated with a
reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly
acquired Parkinson's disease (HR 0.51, CI 0.4–0.55, p < 0.0001).
Conclusion: Simvastatin is associated with a strong reduction in the incidence of dementia and
Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and
Parkinson's disease, which shows only a trend towards significance.
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Dementia is one of the major public health threats that
individuals face as they age. Epidemiological studies sug-
gest that cardiovascular disease, hypercholesterolemia,
hypertension and diabetes are important risk factors for
the development of dementia [1-4]. Some studies suggest
that medications used to treat these risk factors are also
associated with a reduced incidence of dementia [5-10].
Statins are a class of lipid-lowering agents that act by
inhibiting the second enzyme in the cholesterol synthetic
cascade, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase. Many studies have investigated whether
statin treatment might be of benefit for subjects with
dementia or at risk for dementia, but the conclusion
remains ambiguous because of conflicting results [9-15].
Initial studies by our group and that of Jick et al suggested
that statins might be beneficial as a therapy for dementia
[9,10]. Subsequent studies using a cross-sectional analytic
method consistently observed a reduced prevalence and
incidence of dementia among statin users (reviewed by
Sjogren et al[16]). However, the cross-sectional nature of
these studies raises concerns based on the potential for
unanticipated biases including confounding by indica-
tion. These concerns have prompted investigators to pur-
sue other strategies to test whether statins might protect
against dementia.
Two-wave epidemiological studies examined the effects of
statins on incident Alzheimer's disease (AD), but failed to
show a statistical benefit associated with statin use
[11,17]. The number of subjects on statins who developed
incident AD in these two-wave studies was only in the sin-
gle digits, however, which raises concerns about whether
they had sufficient power to detect any putative statin
effects.
Prospective incidence trials have also been examined.
Cognitive arms were added onto ongoing cardiology stud-
ies of which the original goal was to test the efficacy of
statins in preventing cardiovascular incidents [18,19].
These studies also failed to show a reduction in incident
dementia associated with statin use, but concerns can be
raised about the use of an add-on design and whether the
studies were sufficiently powered to detect small effects of
statins on incident dementia.
Two studies were also performed to investigate whether
statins might delay the progression of cognitive decline in
subjects with mild to moderate AD [12,14]. Both of these
studies were quite promising because they showed
reduced progression of measures of cognitive function,
but they were limited by small cohort sizes.
The cumulative review of these various studies leads to a
mixed picture, with multiple studies both suggesting and
refuting that statins might reduce the incidence or pro-
gression of AD.
Powering studies sufficiently to detect modulation of inci-
dent dementia by medication presents a significant chal-
lenge for investigators in the field because only a small
fraction of subjects in any database are using any particu-
lar medication, and only 1–2% of those subjects develop
dementia over the course of short-term follow-up. Large
population databases provide a useful mechanism to
address this problem. For instance, the Decision Support
System (DSS) database of the United States Veterans
Affairs (VA) medical system is a population database that
obtains records from medical centers throughout the USA,
which contains diagnostic, pharmaceutical and demo-
graphic information on approximately 4.5 million sub-
jects [20]. In this study, we used existing information
within this database to obtain prospective data that
allowed us to test the hypothesis that use of statins is asso-
ciated with a reduced incidence of dementia. We found
that simvastatin is associated with a significant reduction
in incident dementia and atorvastatin is associated with a
more modest reduction that is of borderline significance.
Methods
Database
The DSS database contains records from FY 2002 to the
present, although daily records of prescription utilization
are only present from 2003 to the present [20]. We
restricted out study to the years 2003–2005 to allow us to
track prescription usage for every subject. This strategy
also allowed 2002 to be used as a baseline period for our
study to ensure that the subjects did not have a prior diag-
nosis of AD and PD. The database contains records on
approximately 4.5 million subjects and approximately
110 million prescriptions annually. The subjects are
94.4% male and 5.6% female [21].
Exclusion criteria and restrictions
Our analysis was restricted to subjects ≥65 years of age,
who did not have a prior diagnosis of AD [International
Classification of Diseases, revision 9 (ICD-9) code 331.0],
as judged by the absence of a diagnosis of AD during the
baseline period of analysis from 2002–3. For the studies
of Parkinson's disease (PD), a prior diagnosis of PD
(ICD9 code 332.0) was an exclusion criterion.
Subjects selected for further analysis were also those who
had 7 months of continual use of statins after initiation of
pharmacotherapy (a time period that we refer to as the
treatment window), without diagnosis of AD during this
period. Continual use was defined by the presence of
repeat prescriptions refills during the 7-month timePage 2 of 11
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more than 6 weeks in duration. A floating starting point
was used for a subject to establish the exclusion criteria for
a subject and we determined the time to a censoring event
for a subject prospectively. Subjects were analyzed for
continual use of medication only during the first 7
months of analysis. A similar approach was used for estab-
lishing newly acquired Parkinson's disease, using ICD9
code 332.0.
Strategy for analysis
We selected for the ICD9 code 331.0, defined as "senile
dementia of the Alzheimer type". The diagnosis of AD
(ICD 331.0) in the DSS database is not rigorously control-
led and in many cases may not fulfill all of the National
Institute of Neurological Disorders and Stroke/Alzhe-
imer's and Related Disorders Association (NINDS-ARDA)
criteria required for diagnosis of AD, because the DSS
database is a population-derived database. To acknowl-
edge this diagnostic ambiguity, we have used the term
dementia, rather than AD throughout this report. Prior
studies of the VA indicate that the accuracy of the diagno-
sis of AD according to the ICD9 331.0 code is 70–95%,
depending on the medical center (A. McKee, personal
communication). The ICD9 code 332.0 was used for the
diagnosis of PD.
Medications were selected using codes derived from the
national veterans affairs formulary. Covariates previously
linked to AD were used for the analyses. These covariates
used were age, hypertension (ICD9 401–405 and 459.3),
cardiovascular disease (ICD9 277.7, 429.2, 410–414, 428,
430–438, 440 and 794.3), diabetes (ICD9 250) and obes-
ity (ICD9 278). The covariates used for analysis of PD
were similar to those for dementia, except that we also
included use of neuroleptic medications as a covariate
(aripiprazole, clozapine, olanzapine, resperidone,
haloperidol, chlorpromazine, fluphenazine, perphena-
zine, thioridazine, thiothixene and trifluoperazine). The
covariates were measured during the entire analysis
period.
Comparators/models
We used two different approaches to identify reference
groups as comparators for the analyses of subjects taking
statins. The age distribution of each comparator group
was matched to that of the statin group by identifying
records of subjects ≥65 years of age, dividing the subjects
into decades (65–74, 75–84, 85–94, ≥95) and determin-
ing the proportion of subjects in each age group. The com-
parator groups were categorized by age in a similar
manner, and the same proportion of subjects from each
age group was identified. We determined the mean age of
subjects in each of the comparator groups, as well as the
Charlson comorbidity index and number of hospital
admissions in the groups [22].
Cardiovascular comparator
We used a cardiovascular comparator as the primary com-
parator because many statin users have comorbid cardio-
vascular disease. Statin use is frequent among subjects
with cardiovascular disease, and cardiovascular disease is
considered to be one of the major risk factors for demen-
tia. In total, 400000 records were randomly selected from
subjects taking any cardiovascular medication, excluding
those taking statins, using the proportional division
among age groups described above. We chose to use car-
diovascular medication as a criteria rather than any cardi-
ovascular diagnosis to select for subjects who were
sufficiently responsive to the health care system to take
medications, which is analogous to those taking statins.
Warfarin was used as a secondary comparator to allow
comparison to a specific medication, because use of one
identified medication facilitates assessment of potential
modifying factors. Warfarin was chosen because it has not
been reported in the literature to modify the course of
dementia.
Statistical analyses
SAS software (version 9.01; SAS Institute, Cary, NC, USA)
was used for all statistical calculations. Kaplan-Meier sur-
vival curves were plotted to show the rate of events. Cox
proportional hazards models were used to estimate the
association between exposure to statins and risk of
dementia. The covariates described in the analysis section
were included in these models. Point estimates and 95%
confidence intervals (CI) are reported for the adjusted
hazard ratios (HRs). We analyzed several different models
that incorporate increasing numbers of interaction terms.
The results of each model are described in Tables 2 and 4.
Results
Characterization of records from the DSS database
Table 1 describes the characteristics of the populations
analyzed. The mean ages of the comparators and each of
the statins were similar.
We examined the number of hospitalizations and the
Charlson Index during the study period, which is an index
providing a general assessment of chronic disease [22].
The CV comparator and each of the statins had differences
in the Charlson Index that were <4% of the mean stand-
ard deviation for the group, and differences in hospitali-
zation rates that were <15% of the mean standard
deviation for the group (Table 1). The warfarin group had
a hospitalization rate and Charlson Index that were signif-
icantly higher than the values for the other groups (Table
1).Page 3 of 11
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medication. Table 1 shows the number of subjects taking
statins who were ≥65 years old and had 7 months of con-
tinuous use of statin (as defined by continuous prescrip-
tions). Lovastatin, simvastatin and atorvastatin all had
large numbers of prescriptions during the 2003–5 period.
Fluvastatin and pravastatin showed a modest number of
prescriptions, and rosuvastatin was not prescribed to a sig-
nificant degree in the VA system during the 2003–5. We
also analyzed patterns of usage. Use of lovastatin, simvas-
tatin, atorvastatin and pravastatin changed by <50% over
the 3 years of analysis. Use of fluvastatin, however,
increased approximately 40-fold between 2003 and 2005.
The average age of subjects taking statins was 74.6 years,
and was similar for the whole group of statin users (Table
1). Based on these data, we did not pursue further studies
Table 2: Models used for analysis of the effects of statins on incidence of dementia using the Cox proportional survival method.
Model 1 Model 2 Model 3
Variable HR p value 95% Confidence 
limits for HR
HR p value 95% Confidence limits for HR HR p value 95% Confidence 
limits for HR
Atorvastatin
Versus CV 0.80 0.0005 0.71 0.91 0.90 0.09 0.79 1.02 0.91 0.11 0.80 1.02
Age 1.11 <0.0001 1.10 1.12 1.11 <0.0001 1.10 1.11
Hypertension 1.10 0.0590 1.00 1.20
CVD 1.13 0.0005 1.05 1.20
Diabetes 1.12 0.0009 1.05 1.20
Charlson Index 1.78 <0.0001 1.66 1.91
Lovastatin
Versus CV 0.98 0.70 0.89 1.08 0.95 0.32 0.86 1.05 0.95 0.34 0.86 1.05
Age 1.11 <0.0001 1.10 1.12 1.11 <0.0001 1.10 1.11
Hypertension 1.09 0.07 0.99 1.19
CVD 1.12 0.0005 1.05 1.20
Diabetes 1.12 0.0009 1.05 1.20
Charlson Index 1.74 <0.0001 1.62 1.86
Simvastatin
Versus CV 0.45 <0.0001 0.43 0.47 0.45 <0.0001 0.43 0.48 0.46 <0.0001 0.44 0.48
Age 1.11 <0.0001 1.10 1.11 1.11 <0.0001 1.10 1.11
Hypertension 1.07 0.07 1.00 1.15
CVD 1.09 0.0012 1.04 1.15
Diabetes 1.08 0.0034 1.03 1.14
Charlson Index 1.72 <0.0001 1.63 1.81
HR, hazard ratio, CVD, cardiovacular disease, CV, cardiovascular.
Model 1 included an adjustment for the interaction between dementia and age; model 2 included adjustments for the interaction between dementia 
and three disorders associated with increased risk of dementia.; model 3 included adjustments for the interaction between dementia and the 
Charlson Index, which is an index that provides a broad assessment for the amount of chronic disease. For the purpose of analysis of interactions 
with the Charlson Index, subjects with a Charlson Index of 0 or 1 were compared with those with a Charlson Index of ≥2.
Table 1: Characterization of subjects taking statins or in comparator groups.
Drug Name No. of cases Age Average Charlson Index Average no. of hospital stays Cases (%)
Mean SD Mean SD Mean SD
CV 394 739 74.6 5.7 2.0 2.0 0.5 1.5 30.6
Warfarin 53 369 75.9 5.7 2.6 2.3 0.8 1.9 4.1
Atorvastatin 53 869 73.5 5.3 2.3 2.2 0.6 1.6 4.2
Fluvastatin 5 136 74.2 5.6 2.0 2.1 0.4 1.2 0.4
Lovastatin 54 052 74.8 5.6 2.1 2.1 0.4 1.4 4.2
Pravastatin 1 778 73.5 5.3 2.4 2.4 0.5 1.4 0.1
Simvastatin 727 128 74.5 5.6 2.0 2.0 0.4 1.3 56.4
Total 1 290 071 74.6 5.6 2.1 2.0 0.4 1.4 100.0
Column 1, medication group; column 2, the number of subjects ≥65 years who exhibited continuous use of statins for at least 7 months; columns 3 
and 4, mean age and standard deviation (SD); columns 5 and 6, Charlson Index and SD; columns 7 and 8, hospitalization rate and SD; column 9, 
percentage of cases in each group.Page 4 of 11
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Table 4: Models used for analysis of the effects of statins on incidence of Parkinson's disease using the Cox proportional survival 
method. (A) Atorvastatin; (B) lovastatin; (C) simvastatin. Model 1 included an adjustment for the interaction between PD and age. 
Model 2 included adjustments for the interaction between PD, three disorders associated with increased risk of PD and neuroleptic 
use. Model 3 included adjustments for the interaction between dementia, the Charlson Index and neuroleptic use. For the purpose of 
analysis of interactions with the Charlson Index, subjects with a Charlson Index of 0 or 1 were compared with those with a Charlson 
Index of ≥2. Cox Survival Models for Incidence of Parkinson's Disease. A. Atorvastatin vs CV Comparator
Model 1 Model 2 Model 3
Variable HR p value 95% Confidence 
limits for HR
HR p value 95% Confidence limits for HR HR p value 95% Confidence 
limits for HR
Atorvastatin 0.90 0.15 0.79 1.04 0.96 0.59 0.84 1.11 0.99 0.90 0.86 1.14
Versus CV 1.05 <0.0001 1.05 1.06 1.05 <0.0001 1.05 1.06
Age 1.00 0.97 0.90 1.12
Hypertension 1.18 <0.0001 1.09 1.27
CVD 1.12 0.0059 1.03 1.21
Diabetes 5.12 <0.0001 4.62 5.68 4.97 <0.0001 4.48 5.51
Charlson Index 1.33 <0.0001 1.23 1.44
Lovastatin
Versus CV 1.09 0.15 0.97 1.22 1.06 0.33 0.95 1.18 1.09 0.13 0.98 1.22
Age 1.05 <0.0001 1.04 1.06 1.05 <0.0001 1.04 1.06
Hypertension 0.99 0.85 0.81 1.10
CVD 1.20 <0.0001 1.11 1.29
Diabetes 1.13 0.0001 1.05 1.23
Charlson Index 5.16 <0.0001 4.66 5.71 5.02 <0.0001 4.53 5.55
Simvastatin 1.32 <0.0001 1.22 1.43
Versus CV
Age 0.50 <0.0001 0.47 0.53 0.50 <0.0001 0.47 0.53 0.50 <0.0001 0.49 0.55
Hypertension 1.05 <0.0001 1.05 1.06 1.05 <0.0001 1.05 1.06
CVD 0.97 0.42 0.89 1.05
Diabetes 1.21 <0.0001 1.14 1.28
Charlson Index 1.11 0.0012 1.04 1.18
Atorvastatin 5.26 <0.0001 4.85 5.70 5.08 <0.0001 4.69 5.50
Versus CV 1.44 <0.0001 1.36 1.53
HR, hazard ratio, CVD, cardiovacular disease, CV, cardiovascular.
Model 1 included an adjustment for the interaction between dementia and age; model 2 included adjustments for the interaction between dementia 
and three disorders associated with increased risk of dementia.; model 3 included adjustments for the interaction between dementia and the 
Charlson Index, which is an index that provides a broad assessment for the amount of chronic disease.
Table 3: Statistical parameters characterizing the results obtained from Kaplan-Meier survival curves. Characterization of Dementia 
Incidence in the Statin Groups and CV Comparator
Dementia cases Time to incidence for 
dementia cases (months)
Time to end of study for non-dementia 
cases (months)
Drug Sample size (n) n % Mean SD Mean SD Model 3: HR for incidence 
of dementia vs CV (95% CI)
CV 394 739 3359 0.85 19.8 8.0 30.3 8.6
Atorvastatin 53 869 275 0.51 19.5 7.7 23.9 11.6 0.91 (0.80–1.02)
Lovastatin 54 052 439 0.81 19.1 7.9 29.7 8.1 0.95 (0.86–1.05)
Simvastatin 727 128 2647 0.36 19.3 7.8 29.1 8.0 0.46 (0.44–0.48)
CV, cardiovacular.
Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 
4, percentage of dementia cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between 
start of the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the 
analytic period and point at which subjects not receiving a diagnosis of dementia were censored due to the end of the analytic period, and SD.
Hazard ratio for incidence of dementia based on the results from model 3 (Table 2).
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pravastatin was too few to produce reliable information.
Fluvastatin had more subjects but was confounded by a
very large increase in use; the large increase in subjects
using fluvastatin between the start and end of the analysis
meant that the average duration that subjects would be
exposed to the medication was much less than for lovas-
tatin, simvastatin or atorvastatin.
Statins are associated with reduced rate of incident 
dementia
To determine whether statins were associated with lower
rates of incident dementia we examined the cumulative
incidence curves for each of the statins using the CV com-
parator and adjusted for covariates using the hazard rates
by the Cox proportional hazard method. We used three
different models for the analysis; results are shown in
Table 2.
Model 1 used an adjustment only for age. Model 2 used
adjustments for three major disorders that are known to
be important risk factors for AD, cardiovascular disease,
hypertension and diabetes. Model 3 used adjustments for
the Charlson Index [22]. The adjusted survival curves
using Model 3 for the adjustments are shown in Figure 1.
Atorvastatin showed a reduction in the HR that was signif-
icant in model 1, borderline significant in model 2 (HR =
0.90, CI 0.79–1.02, p < 0.1) and not significant in model
3 (Table 2A; fig. 1A, D). Lovastatin did not show a signif-
icant reduction in the HRs (Table 2B; fig. 1B, D). Simvas-
tatin showed a strong reduction in the HR for incident
dementia that was significant in each of the models, with
a HR in Model 3 of 0.46 (CI 0.44–0.48 p < 0.0001) (Table
2C; fig. 1C, D). Statistical parameters describing the num-
bers of cases and censoring are shown in Table 3. The
mean time to incident dementia was similar for each of
the groups. Cases that reached the end of the study with-
out a diagnosis of dementia were censored. The time to
censoring was similar for all groups, except for the atorv-
astatin group (Table 3). The time to censoring for the ator-
vastatin group was about 6 months less than that for the
other groups, which probably reflects the more recent
introduction of atorvastatin to the VA system, leading to a
more recent initiation of subjects on atorvastatin than for
the other groups (Table 3).
To understand how the type of comparator might influ-
ence our results, we also determined the association
between statins and odds of incident dementia using a
specific medication, warfarin (Figure 2). Simvastatin
showed reduced HRs for incident dementia when tested
against warfarin. The adjusted HR, using model 3, was
0.46 (CI 0.42–0.51, p < 0.0001) against warfarin (Figure
2). Neither atorvastatin nor lovastatin showed a signifi-
cant reduction in the HR for incident dementia compared
with warfarin (Figure 2).
Statins are also associated with reduced incidence of 
Parkinson's disease
The data presented above indicate that statins are associ-
ated with a reduced incidence of dementia, but do not
provide insight into whether this benefit is selective for
dementias or extends to other neurodegenerative diseases.
To investigate this question, we examined the effects of
statin use on the incidence of PD. The incidence of PD was
investigated in subjects taking atorvastatin, lovastatin or
simvastatin, and compared with the CV comparator. We
adjusted for cardiovascular disease, hypertension, diabe-
tes, and use of neuroleptics. Neither atorvastatin nor lov-
astatin were associated with significant effects in any of
the models (Table 4; Figure 3A, B, D). We observed that
simvastatin was also associated with a reduced incidence
of PD in all models, with the data for model 3 correspond-
ing to a HR of 0.51 (CI 0.49–0.55, p < 0.0001) (Table 4;
Figure 3C, D). Statistical parameters describing the num-
bers of cases and censoring are shown in Table 5. The
mean time to incident PD was similar for each of the
groups, except for the atorvastatin group, which exhibited
a smaller time to censoring (Table 5).
Discussion
We previously reported that statins are associated with a
reduced prevalence of dementia. Subsequent studies on
this subject produced mixed results. We hypothesized that
the ambiguity might arise from differences in efficacy
among different statins, variation in responses in the pop-
ulation and inadequate sample size to power the studies
sufficiently to detect such modifying factors. To address
these issues, we used a very large population database to
perform prospective studies examining the effects of stat-
ins on the incidence of dementia. The prospective format
used in the current study avoids effects arising from
changes in statin use associated with the diagnosis of
dementia, and could account any differences observed
between our previous study and this one [9]. We found
that simvastatin is associated with a reduced incidence of
both dementia and PD.
Studies using population databases have strengths and
weaknesses that must be considered in interpreting
results. The large numbers of subjects provides enormous
power for analyses and the structure of the databases
allows for prospective studies of incidence. The strong sta-
tistical power associated with the large number of subjects
also enables detailed subcategorization of the cohorts,
which can provide novel insights. For instance, the ability
to subdivide statin users by each statin allowed us to
examine the effects of three different statins: atorvastatin,
lovastatin and simvastatin. The ability to track subjectsPage 6 of 11
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dementia cases, which represents a significant difference
from our previous study on statins, which examined prev-
alent cases [9]. The focus on incident cases in the current
study avoided problems associated with some of the
biases that can occur in studies of prevalence, and could
explain the differences observed between the two studies
[9]. In addition, the covariates provide some adjustment
for confounding by indication.
The nature of the prospective study, however, is quite dif-
ferent from that in a randomized clinical trial. Subjects on
medications in population databases necessarily have
comorbid illnesses, whereas random clinical trials can
control the type or degree of comorbid illness or even
exclude subjects with comorbid illnesses. Assessing the
nature of the sample and the comparators correctly
becomes a very important issue in studies examining pop-
ulation databases. We used two comparators, a CV com-
parator and warfarin. We feel that the CV comparator is
the more robust, because the strong link between hyperc-
holesterolemia and cardiovascular disease suggests that
the statin group should resemble the CV comparator
group. Warfarin was chosen as a comparator to provide a
specific medication as a reference, although any particular
medication will always have particular concerns relevant
to that medication. We chose warfarin because it had not
been shown to modify the course of dementia. Warfarin is
used to treat many types of vascular disease, including
deep vein thrombosis, stroke and atrial fibrillation [23].
Despite use of warfarin to treat vascular disease, referenc-
ing simvastatin to warfarin produced results that were
substantially similar to those observed when referencing
simvastatin to the CV comparator.
Cumulative incidence curves for dementia in subjects taking statinsFigure 1
Cumulative incidence curves for dementia in subjects taking statins. Cumulative incidence curves are shown for sub-
jects ≥65 years who were taking each statin. The CV comparator was used as the comparison group. Dark blue line, CV com-
parator; light blue line, confidence intervals for the CV comparator curve; red line, statin group; pink line, confidence intervals 
for the statin curves. The first 7 months represent the obligate period for drug treatment, during which subjects were treated 
and any subjects developing dementia were eliminated from the analysis. (A) Atorvastatin; (B) lovastatin; (C) simvastatin; (D) 
summary of hazard ratios for each of the statins using model 3.Page 7 of 11
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this group was not designed as a reference at the outset of
the study. The incidence of dementia among subjects tak-
ing lovastatin was similar to that of the CV comparator,
and well above that of the simvastatin group. The case mix
of the simvastatin and lovastatin groups might resemble
each other more than the case mixes for the other compa-
rators, yet simvastatin showed a greater efficacy for reduc-
ing dementia, although it is important to be cognizant
that simvastatin is a newer medication than lovastatin,
which could lead to a selection bias. The strength of reduc-
tion in dementia for simvastatin compared with lovasta-
tin is consistent with many studies showing that
simvastatin reduces measures of plasma cholesterol more
effectively than lovastatin [24,25]. The presence of a
strong and significant difference in HRs for dementia
between these two groups (lovastatin and simvastatin)
that are congruent for statin use supports the hypothesis
that the efficacy of simvastatin arises from the action of
simvastatin rather than from a prescription bias.
Analysis of the frequency of hospitalizations and the
Charlson Index were used to compare the different groups
in this study and used to control for comorbid disease.
The CV comparator and each of the statins exhibited sim-
ilar hospitalization rates and Charlson indices, which sug-
gests that these groups exhibited similar rates of comorbid
illnesses. The warfarin group showed elevated Charlson
indices and elevated hospitalization rates, which is con-
sistent with a hypothesis that these groups had a higher
general rate of morbidity than most of the other groups.
The potential differences in comorbid illnesses that might
exist among the groups did not exert strong effects on the
resulting HRs. When we used models that adjusted for
potential interactions between Alzheimer's disease and
other chronic illnesses, we did not observe a strong
change in the size of the HR describing the relationship
between use of simvastatin and incident dementia.
Quantitative indices of subject health, such as laboratory
values or imaging studies, are not available in the DSS
database, in contrast to databases prepared by academic
investigators and in clinical trials [20]. The absence of
quantifiable measures means that we were not able to
determine the degree of cholesterol reduction associated
with each statin, nor were we able to quantify cognition.
Although we used the ICD9 diagnostic code for senile
dementia of the Alzheimer type, 331.0, misdiagnosis
occurs, thus we used the generic term, dementia. Diag-
noses of AD in population databases are also not rigor-
ously controlled, and the diagnostic measures often do
Table 5: Statistical parameters characterizing the results obtained from Kaplan-Meier survival curves for PD. Characterization of 
Parkinson's Disease Incidence in the Statin Groups and CV Comparator
Dementia 
cases
Time to incidence for 
dementia cases (months)
Time to end of study for 
non-dementia cases (months)
Drug Sample size (n) n % Mean SD Mean SD Model 3: HR for incidence of dementia 
vs CV (95% CI)
CV 392 966 2417 0.62 19.5 8.0 30.3 8.6
Atorvastatin 53 701 224 0.42 17.9 7.7 24.0 11.5 0.99 (0.86–1.14)
Lovastatin 53 711 350 0.65 18.8 7.9 29.7 8.1 1.09 (0.98–1.22)
Simvastatin 725 820 2116 0.29 19.3 7.9 29.1 8.0 0.51 (0.49–0.55)
Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 
4, percentage of PD cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between start of 
the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the analytic period 
and point at which subjects not receiving a diagnosis of PD were censored due to the end of the analytic period, and SD.
Hazard ratio for incidence of PD based on the results from model 3 (Table 4).
Cumulative incidence curves using model 3 for incident de entia in subjects taking tati sFigure 2
Cumulative incidence curves using model 3 for inci-
dent dementia in subjects taking statins. The incidence 
of dementia in subjects ≥65 years were determined for sub-
jects taking each statin with reference to warfarin. The 
graphical data show the hazard ratios for incident dementia ± 
95% confidence interval.Page 8 of 11
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ies indicate that the diagnoses of AD in the VA databases
are 70–95% accurate [26]. The presence of ≥70% of cases
that probably do have AD suggests that the reduction in
incidence of dementia associated with statin use observed
in our study also applies to AD, although the exact degree
is risk reduction for AD might differ from that observed in
our study.
The strength of reduction of incidence of dementia
observed with simvastatin is striking. Further studies are
required to determine whether this effect represents a bio-
logical action of simvastatin or a statistical bias skewing
results obtained from the DSS database. If the reduction
in incident dementia derives from biological actions of
simvastatin, studies in the literature suggest potential bio-
logical mechanisms that might contribute to this action.
Prior studies indicate that simvastatin is more effective
than pravastatin or lovastatin at modifying some meas-
ures of lipid metabolism, such as reductions in cholesterol
and LDL, and increases in HDL. Simvastatin has a similar
efficacy as atorvastatin with respect to reducing measures
of lipid metabolism [25,27]. Simvastatin is better that
atorvastatin on some measures (e.g., raising HDL), but
atorvastatin is better than simvastatin on other measures
(e.g., lowering LDL) [25,28-30]. The size of the difference
in HR that we observed for simvastatin compared with the
other statins appears larger than that observed in studies
examining vascular lipid parameters. This raises the possi-
bility that the putative benefit of simvastatin arises from
another contributing factor. One factor could be the abil-
ity to penetrate the blood-brain barrier. The statins differ
in their lipophilicity and ability to cross the blood-brain
barrier, with the rank order of permeabilities being lovas-
Cumulative incidence curves using model 3 for incident PD in subjects taking statins (Table 4)Figure 3
Cumulative incidence curves using model 3 for incident PD in subjects taking statins (Table 4). Cumulative inci-
dence curves are shown for subjects ≥65 years who were taking each statin. The CV comparator was used as the comparison 
group. Dark blue line, CV comparator; light blue line, confidence intervals for the CV comparator curve; red line, statin group; 
pink line, confidence intervals for the statin curves. The first 7 months represent the obligate period for drug treatment, during 
which subjects were treated and any subjects developing dementia were eliminated from the analysis. (A) Atorvastatin; (B) lov-
astatin; (C) simvastatin; (D) summary of hazard ratios for each of the statins using model 3.Page 9 of 11
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atypical, because of its strong efficacy but intermediate
permeability. The combination of lipophilicity and effi-
cacy gives simvastatin a unique pharmacological profile
compared with the other statins. These factors might lead
simvastatin to be more potent than lovastatin. Atorvasta-
tin has strong anti-inflammatory properties, but the ina-
bility of atorvastatin to penetrate the blood-brain barrier
might reduce its efficacy in preventing neurodegenerative
disease [35]. Further studies are needed to clarify this
issue.
The ability to examine multiple disorders is a salient
strength of population databases such as the DSS data-
base. In this study, we also examined the efficacy of statins
towards PD. The association of statins with reduced inci-
dence dementia and PD raises the possibility that the
action of statins against these diseases shares a common
mechanism. Many investigators have noted that statins
reduce inflammation, osteoporosis, and fractures, as well
as diseases directly caused by heart disease [40-42].
Inflammation contributes to the pathophysiology of AD
and PD. We recently observed that subjects with severe AD
pathology who were taking statins show less inflamma-
tion than those not taking statins [43]. It is possible that
the putative ability of statins to reduce inflammation con-
tributes to the reduction in incidence of degenerative dis-
ease associated with simvastatin.
Conclusion
Simvastatin is associated with a significant reduction in
incident dementia and incident Parkinson's disease. Ator-
vastatin is associated with a modest reduction in incident
dementia that is of borderline significance when age is
included as a covariate, but insignificant when other
comorbid diseases are included as covariates. Further
studies are required to determine whether this effect rep-
resents a biological action of simvastatin or an unantici-
pated statistical bias present in the DSS database.
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